Electrocardiographic characterization of myocardial scar in presence of conduction abnormality by Wieslander, Björn
From Department of Molecular Medicine and Surgery (MMK) 
Karolinska Institutet, Stockholm, Sweden 
ELECTROCARDIOGRAPHIC 
CHARACTERIZATION OF MYOCARDIAL 
SCAR IN PRESENCE OF CONDUCTION 
ABNORMALITY 
Björn Wieslander 
 
Stockholm 2016 
 
  
 
 
 
Cover: 
Superimposed 12-lead ECG from a patient with  
left bundle branch block. Hidden beneath  
the transparent electrocardiographic signal  
is a late gadolinium enhancement  
cardiovascular magnetic resonance image 
with evidence of previous myocardial infarction. 
All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by Eprint AB 2016 
© Björn Wieslander, 2016 
ISBN 978-91-7676-420-6  
 
 
 
 
 
 
Electrocardiographic characterization of myocardial scar 
in presence of conduction abnormality 
 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
 
Publicly defended in Lilla Salen, Q3, Astrid Lindgren Children’s Hospital, 
Karolinska University Hospital 
Friday November 4th 2016 at 9:00 A.M. 
By 
Björn Wieslander 
Principal Supervisor: 
Martin Ugander, MD, PhD  
Karolinska Institutet 
Department of Molecular Medicine and Surgery 
Division of Clinical Physiology 
 
Co-supervisors: 
David G. Strauss, MD, PhD 
Karolinska Institutet 
Department of Molecular Medicine and Surgery 
Division of Clinical Physiology 
 
Andreas Sigfridsson, PhD 
Karolinska Institutet 
Department of Molecular Medicine and Surgery 
Division of Clinical Physiology 
 
Kenneth Caidahl, MD, PhD  
Karolinska Institutet 
Department of Molecular Medicine and Surgery 
Division of Clinical Physiology 
 
Opponent: 
Olujimi Ajijola, MD, PhD 
University of California Los Angeles 
Cardiac Arrhythmia Center and Neurocardiology 
Research Center of Excellence 
 
Examination Board: 
Erik Hedström, MD, PhD 
Lund Universitet 
Department of Clinical Sciences 
 
Frieder Braunschweig, MD, PhD 
Karolinska Institutet 
Department of Medicine 
 
Sverker Jern, MD, PhD 
Göteborgs Universitet 
Department of Molecular and Clinical Medicine 
 
 

  
 
 
 
“The chains of habit are too weak to be felt  
until they are too heavy to be broken” 
 
Samuel Johnson

  
ABSTRACT 
Presence, extent and localization of myocardial scar constitute prognostic clinical information 
that can influence therapeutical decisions. Cardiovascular magnetic resonance imaging with 
late gadolinium enhancement (CMR-LGE) is the preferred method to image myocardial scar 
in vivo but is resource intensive and has contraindications. The 12-lead electrocardiogram 
(ECG) is less accurate but inexpensive and widely available. Adaptations of the Selvester 
QRS score, an ECG analysis system for scar characterization, were developed in 2009 for use 
in presence of conduction abnormalities such as left bundle branch block (LBBB). Prior to 
the work described in this thesis, these newly developed Selvester QRS score adaptations had 
only been preliminarily validated against CMR-LGE.  
The overall aim of the thesis was to evaluate the diagnostic performance and clinical utility in 
predicting response to cardiac resynchronization therapy (CRT) of the 2009 Selvester QRS 
score for use in the presence of conduction abnormality, and to revise the LBBB version 
(2009 LBSS) based on empirical CMR-LGE data.  
We found that the ECG criteria comprising the 2009 LBSS had modest ability to localize 
CMR-LGE verified myocardial scar within the left ventricle (LV) (study I). Next, we 
evaluated the ability of the Selvester QRS score adaptations for use in LBBB, right bundle 
branch block (RBBB), left anterior fascicular block (LAFB) and combined RBBB+LAFB to 
identify and quantify myocardial scar as verified by CMR-LGE. The results revealed a 
tendency of the ECG method to overestimate scar burden and presence compared to CMR-
LGE (study II). We then investigated the individual specificity of the 46 QRS morphology 
criteria that comprise the 2009 LBSS and found that certain criteria hade prohibitively low 
specificity, likely causing the overestimation of myocardial scar size and presence found 
previously (study III). We further evaluated the ability of all Selvester QRS score adaptations 
to predict response to CRT in a randomized cohort. Scar burden estimated by QRS scoring 
did predict clinical outcome in both study arms but could not distinguish who benefitted from 
CRT in terms of reduced risk of heart failure event or death (study IV). Finally, we assembled 
a large training dataset of 325 patients in which we performed careful continuous 
measurements on digital ECGs. We subsequently compared ECG measurements to 
myocardial scar quantified by CMR-LGE. We achieved an improved method of ECG scar 
detection in LBBB compared to the 2009 LBSS that remains to be tested in an independent 
population. 
The Selvester QRS score adaptations for presence of conduction abnormalities tends to 
overestimate scar and has limited correlation with CMR-LGE verified scar presence and 
extent. The 12-lead ECG likely contains insufficient information for accurate quantification 
of myocardial scar in LBBB. However, it may still be possible to distinguish between scar 
presence and absence using the 12-lead ECG in presence of LBBB. 
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1 INTRODUCTION 
 
The focus of this thesis is the electrocardiographical (ECG) diagnosis of myocardial scar in 
patients with an abnormally functioning cardiac conduction system. Normally, the innate 
electrical conduction system within the heart ensures an optimized coordinated contraction 
of the heart muscle cells, the cardiomyocytes. In particular, a defect in the conduction 
system known as left bundle branch block (LBBB) can markedly disrupt the heart’s ability 
to pump efficiently. Further, the normal appearance of the ECG is altered extensively when 
LBBB is present which makes diagnosis of both acute myocardial infarction and chronic 
myocardial scar challenging. In addition, there is evidence that myocardial scar renders 
therapies aimed at the remedy of LBBB-induced cardiac dyssynchrony ineffective.  
The first chapter of the thesis will discuss the historical development of the ECG until the 
recent development of a system to derive from it information about scar in patients with 
LBBB. Further, the genesis and consequences of myocardial scar will be reviewed, as well 
as current means and importance of diagnosing and characterizing myocardial scar in vivo. 
 
1.1 EARLY HISTORY OF ELECTROCARDIOLOGY 
 
The biological role of electricity has been studied during the last centuries in parallel to the 
long process of discovering electricity itself. Although not the first to discover the generation 
of electric potentials in the heart, Willem Einthoven was the first to examine the spatial 
orientation over time of the cardiac electrical potentials to distinguish health from pathology1. 
Using his newly invented sensitive string galvanometer Einthoven measured the voltage 
differences between different body parts and recorded the results. A publication from 19062 
contained descriptions of the electrocardiographic (ECG) appearance of several distinct 
pathologies in a subset of the same ECG leads that are routinely used today.  
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Figure 1. The normal electrocardiogram
 
Figure 1: The spatial directions of the extremity leads I-III and augmented vectors right, left 
and foot, abbreviated aVR, aVL and aVF, are shown in the upper left panel. The spatial 
directions of the precordial leads V1-V6 are displayed in the upper middle panel. A 
schematic representation of the typical electrical signal during one heart cycle is shown in 
the upper right panel. The P-wave and the QRS complex reflect the depolarization the atria 
and ventricles, respectively, and the T-wave results from the repolarization of the ventricles. 
Einthoven changed the waveform denominations from ABCD into letters from the second half 
to the alphabet, PQRST, to denote that a correction formula had been applied to compensate 
for the insensitivity of early galvanometers3. The letters N and O were not used because they 
had other widely accepted mathematical meanings. The lower panel shows a normal 
standard 12-lead ECG with limb leads displayed according to the Cabrera sequence4 (aVL, I, 
-aVR, II, aVF, III), as initially suggested by Fumagalli. The cabrera sequence is routinely 
used in Sweden among several other European countries. Figure adapted from Koelsch et al5 
with permision.  
The construction of a standard ECG was subsequently modified to include nine additional 
leads through the invention of unipolar precordial leads by Frank Norman Wilson in 19346 
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and the amplification of these unipolar leads by Emanuel Goldberger in 19427. This 
expansion resulted in the standard ECG as it is most frequently encountered today (figure 1), 
which enabled more precise diagnosis of a multitude of cardiac diseases.  
In parallel, researchers explored the concept describing the summary of the wavelike spread 
of electrical activity within the heart as a vector changing over time. Mann became the first to 
describe the monocardiogram8, which later came to be known as the vectorcardiogram 
(VCG). The contribution of the VCG was the more intuitive and direct approach of 
distinguishing disease from health by the normal or abnormal pattern of the three-
dimensional vector loop (figure 2). 
Figure 2. Vectorcardiogram 
 
Figure 2. An example of a vectorcardiogram (VCG). At each measurement of voltage, the 
potential differences between the leads are used to calculate the magnitude and direction of 
the net vector of the heart’s depolarization in three-dimensional space. As the vector changes 
over time, its trace forms a “vector loop”. In the figure, the blue lines show the vector loops 
of five ventricle depolarizations. Figure reproduced from Sur et al.9, with permission. 
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 This was in contrast to examining waveforms from individual leads which required 
appreciable spatial imagination on the part of the observer to form a three-dimensional whole 
picture of the electrical events during the cardiac cycle. Ever since, development and 
refinement of criteria to discriminate the presence and grade of various disease processes 
have continued. Both the VCG and the ECG continue to be in use clinically today, although 
the dominating variation has become the 12-lead ECG shown in figure 1. 
 
1.2 ELECTRICAL CONDUCTION SYSTEM OF THE HEART 
 
In parallel with ECG diagnosis of various diseases being sharpened gradually over the 20th 
century, the understanding of the cardiac conduction system was being furthered as well. The 
individual parts of the cardiac conduction system (figure 3) have been characterized both 
histologically and functionally.  
The generation of electrical activity within the heart on a molecular level occurs because 
cardiac muscle cells, like many other types of cells, have the ability to produce action 
potentials (figure 4). An action potential is a process during which a cell produces rapid 
changes of the voltage across the cell membrane. The production of the rapid change of 
voltage is accomplished by the coordinated opening and closing of ion channels in the cell 
membrane. This process requires the body to carefully regulate levels of electrolytes such as 
potassium and sodium in the extra- and intracellular fluid. An action potential can act as a 
signal to trigger intracellular events, such as muscle fiber contraction, and also to trigger 
another action potential in an adjacent cell. Cardiac muscle cells, cardiomyocytes, are 
interconnected electrically through protein complexes termed “gap junctions”10. Therefore, an 
action potential in a single cardiac cell can trigger a wavelike spread of action potentials in 
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the whole heart by triggering action potentials in its neighbor, which in turn can propagate the 
action potential to subsequent layers of cells. 
Figure 3. Schematic drawing of the electric conduction system of the heart 
 
Figure 3. The principal components of the electrical conduction system of the heart: 1. Sino-
atrial (SA) node. 2. Atrioventricular (AV) node. 3. Bundle of His. 4. Left bundle branch. 5. 
Posterior fascicle of the left bundle branch. 6. Anterior fascicle of the left bundle branch. 7. 
Left ventricle. 8. Interventricular septum. 9. Right ventricle. 10. Right bundle branch. Figure 
reproduced under a creative commons license. Original figure by Illustrator Patrick Lynch 
and cardiologist Carl Jaffe, MD, with subsequent modifications by J. Heuser.  
 
Specialized cardiac muscle cells that periodically generate action potentials without need for 
external stimuli were found concentrated primarily in a 10-15 mm by 3 cm area in the upper 
right atrium close to the coronary sinus (figure 3)11. This concentration of cells was termed 
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the “sino-auricular node” by its discoverers11. Today it is more commonly known as the sino-
atrial node or SA-node as the word atria has largely replaced the word auricula, which now 
instead commonly refers to the atria appendages.  
Already in 1839 Purkyně described elongated cardiac cells with double nuclei as a distinct 
feature. These Purkinje fibers were later found through a series of discoveries to have many 
gap junctions making them suitable for rapid conduction of electric signals more so than 
contraction. Furthermore, incremental discoveries showed that these Purkinje cells were 
organized into fibers making up a complex network in the heart, tapering from the bundle 
branches. Activation spreads throughout the heart in a coordinated fashion through the 
conduction system thereby yielding an optimized overall contraction to pump out blood to the 
body efficiently12. Key discoveries included the description of the atrio-ventricular bundle 
named His bundle after its discoverer13, and the discovery of the atrio-ventricular (AV) node 
by Tawara in 190713. 
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Figure 4: Myocyte action potential 
 
Figure 4. The temporal relationship between the ECG signal (A), an action potential of a 
ventricular myocyte (B) and the involved ions flowing across the cell membrane due to the 
orderly and rapid opening, closure and inactivation of transmembrane ion channels (C). The 
QRS complex potential differences at the body surface are induced by currents arising from 
coordinated action potentials in the cardiomyocytes. The letters in panel B reflects the 
positively charged ions principally involved in different phases of the action potential in a 
myocyte: the inward sodium (INa) and calcium (ICa) currents, and the outward potassium 
currents (ITO, IKs, IKr and IK1). Figure reproduced with from George, et al.,14 with permission 
conditioned upon provision in this thesis of the publisher’s web address: 
http://www.tandfonline.com. 
More detailed knowledge of the conduction in the human heart emerged from remarkable 
experiments conducted by Durrer et al15, where healthy human hearts were collected from 
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accident victims and suspended outside the body. Durrer implanted needles into each 
collected and suspended heart according to a coordinate system in order to map out the exact 
sequence of activation of the heart muscle. The results were highly detailed maps of the 
activation sequence of the collected hearts (figure 5), which later served as basis for the 
development of the Selvester QRS score described in a later section of this thesis.  
Figure 5. Durrer’s myocardial activation maps 
 
Figure 5. Transmural myocardial activation maps showing which myocardial areas activate 
simultaneously (isochrones). Timing of activation is color coded, with the colors 
corresponding to milliseconds from start of activation according to the scale at the bottom. 
Notably, the activation starts in the endocardium of three sites in the left ventricle, one 
anterior, one posterior and one septal, corresponding to the most common anatomical 
configuration of three branches of the left bundle branch. Reproduced from Durrer, et al.,15 
with permission. 
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1.2.1 Conduction abnormalities 
 
Einthoven16 described in his 1925 Nobel lectures a patient with an unusually broad QRS 
complex thought to represent a blockage of the left bundle branch. Since then, ECG criteria 
have evolved17 for blockages at various sites in several combinations and the most commonly 
used are described in recent guidelines of the American Heart Association (AHA)18. 
However, the criteria for several different conduction abnormalities still continue to evolve. 
Recently, new stricter criteria for left bundle branch block (LBBB) have been published by 
Strauss, et al,19 based on invasive electrophysiological measurements by Auricchio and 
colleagues20. Importantly, there is a sizeable inter-individual anatomical variation in the 
conduction system downstream from the bundle of His21, as shown in figure 6. These 
variations likely impact the effects of blocks at various levels of conduction system upon the 
ventricular depolarization reflected in the QRS complex of the ECG. Despite this 
heterogeneity, several distinct categories of conduction abnormalities have been characterized 
according to ECG appearance, as described below. 
Figure 6. Anatomical variations of the left bundle branch 
 
 
 
 
 
 
 
 
 
Figure 6. The sketches show reconstructions of the left bundle branch anatomy from twenty 
human hearts, illustrating the anatomical heterogeneity of the conduction system. 
Reproduced from Demoulin, et al.,22, with permission. 
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1.2.1.1 Left bundle branch block 
As the name suggests, LBBB denotes a condition in which conduction in the left bundle 
branch is absent. This markedly alters the LV activation pattern. Instead of near simultaneous 
multisite activation as shown in Durrer’s maps in figure 5, the LV is activated from the right 
side of the septum to the lateral wall in a sequential manner as shown in figure 7, panels A 
and B. This tends to result in a significant delay in the activation of the lateral wall that can be 
visualized in by functional CMR imaging as shown in figure 7, panel C.  
As shown in figure 7, panel A, the ECG typically reflects this altered activation pattern by a 
deep broad terminal negative deflection in leads V1 and V2. There has been some evidence 
that other cardiac causes may mimic this ECG appearance as demonstrated by Strauss19, who 
suggested the following alternate criteria: terminal negative deflection in lead V1, QRS 
duration of ≥130 ms for women and ≥140 ms for men and presence of mid QRS notching or 
slurring. The notching or slurring in the mid-period of the QRS complex is thought to result 
from a change of wavefront direction occuring when the right-to-left activation of the septum 
reaches the LV endocardium. Invasive catheter measurements23 have shown that patients 
meeting traditional LBBB criteria as described by the AHA18 are readily divided into two 
distinct cohorts that have an LV endocardial activation time of longer than or clearly shorter 
than 40 ms23.  
In principle, any myocardial disease process affecting the left bundle may cause LBBB. 
Cardiac disease and age24 have been found to be the greatest risk factors for developing it. 
Known causes, other than cardiomyopathies in general, include selective calcification of the 
conduction system25 and surgical repair of the aortic valve26. It has been shown that patients 
with cardiomyopathy and LBBB are less likely to have had a large anteroseptal infarction 
than patients with RBBB27, suggesting that the left bundle is less vulnerable to occlusion of 
the left anterior descending (LAD) artery. Prognostically, LBBB has shown to be an adverse 
sign28, 29. 
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Figure 7. Electrical and mechanical delay of the left ventricular lateral wall in LBBB 
 
Figure 7. Panel A: A schematic model of the activation pattern of the heart in presence of left 
bundle branch block (LBBB), with areas of the same color being activated within the same 10 
ms (isochrones). The resulting vector loop (upper right) and QRS complex appearance in the 
precordial leads is shown. Noticeably, sequential activation of the left ventricle (LV) from the 
right side of the septum gives rise to a leftward and posteriorly directed activation wavefront 
causing the characteristic negative deflection in the septal leads V1 and V2 and positive 
deflections in the lateral leads V5 and V6. The mid-QRS notch required by the Strauss 
criteria for LBBB19 is thought to reflect the change of wavefront direction resulting from 
septal breakthrough of activation to the septal LV endocardium. Panel B: An endocardial 
map obtained through catheterization, with color-coded isochrones showing the delayed 
electrical activation of the blue colored lateral LV wall. Panel C shows functional cine CMR 
images from an LBBB patient in study V in four-chamber view. The three timeframes shown 
highlight the initial activation of the septal wall in the middle image followed by contraction 
of the lateral wall in the far right image. Panels A and B are adapted from Strauss, et al.30 
and Fantoni, et al.23, respectively, with permission. Abbreviations: LV = left ventricle. RV = 
right ventricle.  
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1.2.1.2 Other conduction abnormalities 
Beyond LBBB, there are multiple other specific conduction abnormalities with individual 
pathophysiologies, prognostic significance and ECG criteria. These include right bundle 
branch block (RBBB), left anterior and posterior fascicular blocks (LAFB and LPFB, 
respectively), non-specific intraventricular conduction delay (IVCD), several types of atrio-
ventricular (AV) block as well as combinations of the above. The AV-block types disrupt the 
connection between the atria and the ventricles to a varying degree, and their 
pathophysiology and effects fall outside the scope of this thesis. The other conduction 
abnormalities largely share causes with LBBB. It has been found that RBBB is associated 
with the presence of large anteroseptal infarction27 in patients with cardiomyopathy to a 
higher degree than LBBB. This suggests that the right bundle is more vulnerable to ischemic 
injury due to anatomical reasons. Although patients with HF and other conduction 
abnormalities than LBBB do not seem to respond well to CRT31, both RBBB and LAFB have 
been shown to carry prognostic significance with regards to mortality and morbidity32-34. 
 
1.3 HEART FAILURE 
 
The normal function of the heart is to pump sufficient blood to meet the metabolic demands 
of the body. Heart failure (HF) is said to occur when the heart can no longer perform this 
function. The prevalence of HF is high world wide, particularly in the developed world with 
an estimated lifetime risk of 20% for Americans under 40 years of age35. Furthermore, 
prognosis for those affected is comparable to many malignant diseases with approximately 
50% mortality within 5 years of diagnosis35. 
Although inability to meet the body’s perfusion demand is a seemingly simple definition, it is 
not always easy to objectively determine whether HF is present in practice. The AHA state in 
their 2013 HF management guidelines that: “There is no single diagnostic test for HF 
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because it is largely a clinical diagnosis based on a careful history and physical 
examination”35. Yet, there are clinical signs, laboratory tests and imaging methods that can 
help the clinician to elucidate whether the hallmark symptoms of HF such as shortness of 
breath and fluid retention are due to malfunction of the heart or something different. 
Clinical signs include the aforementioned hallmark symptoms, swelling of the legs, 
abdomen and/or neck veins and crackles upon lung auscultation. The most utilized 
laboratory test in diagnosing and grading HF is blood level of brain natriuretic peptide 
(BNP), a compound released by cardiomyocytes when cardiac muscle tissue is stretched, 
e.g. because of volume overload36. Imaging and other investigative modalities used 
clinically in determining presence of HF or its many causes include ECG, 
echocardiography, cardiac magnetic resonance imaging (CMR) and myocardial 
scintigraphy, with or without exercise/pharmacological stress, as well as invasive heart 
catheterization.  
Heart failure has many causes, all of which impair the heart’s ability to pump blood. A 
detailed review of these causes, their pathophysiologies and appropriate treatments falls 
outside the scope of this thesis, but an overview of cardiomyopathies that can cause HF is 
displayed in figure 8. Causes that more often result in myocardial scarring are described in 
more detail below.  
A widely used scale to grade the severity of HF is the New York Heart Association 
(NYHA) functional classification (table 1)37. 
Table 1. New York Heart Association functional classification 
Class Patient Symptoms 
I No limitation of physical activity. 
II Slight limitation of physical activity. Comfortable at rest.  
III Marked limitation of physical activity. Comfortable at rest. 
IV Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. 
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Figure 8. Overview of cardiomyopathies and treatment of heart failure 
 
Figure 8. Summary of broad categories of cardiomyopathies causing HF. Reproduced from 
Drazner, et al.,38 with permission. 
 
1.4 MYOCARDIAL SCAR 
 
When human myocardium is damaged, it is typically replaced by fibrous tissue, comprised 
mainly of collagenous extracellular matrix and fibroblasts. When the fibrotic process is 
focal, the resulting area of fibrous tissue is commonly referred to as myocardial scar. 
Myocardial scar cannot contract and thus cannot contribute to myocardial function.  
1.4.1 Causes 
 
There are several mechanisms through which healthy myocardium may be damaged and 
subsequently replaced by myocardial scar. These mechanisms are frequently divided into 
ischemic (infarction) and non-ischemic causes, and the latter category includes myocarditis, 
hypertrophic cardiomyopathy and dilated cardiomyopathy, among many others39. 
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1.4.1.1 Ischemic etiology of myocardial scar 
Cardiac ischemia occurs when the heart itself is deprived of the blood flow it needs in order 
to function normally. When ischemia is severe and lasts for hours or more, cardiomyocytes 
undergo necrosis from the endocardium and outward, and acute myocardial infarction is 
manifest. The typically decades long pathophysiologic process of coronary atherosclerosis 
preceding myocardial infarction creates conditions conducive to complete coronary 
occlusion, often caused by plaque rupture and clot formation. Myocardial infarction can also 
occur when coronary blood flow is restricted by protracted coronary spams or if the 
capability of the blood stream to deliver oxygen is impaired for other reasons such as severe 
hemorrhage or anemia.  
1.4.1.2 Non-ischemic etiologies of myocardial scar 
As HF progresses, the end stage is typically a state of dilated cardiomyopathy (DCM) in 
which the heart’s walls are thinned out and the heart chambers are enlarged. At this stage, the 
normal orderly arrangement of cardiomyocytes can get disrupted on a histological level40 and 
patches of myocardial scar can appear throughout the cardiac muscle tissue. In particular, this 
type of scarring tends to occur at sites exposed to mechanical stress such as the insertion 
points of the right ventricular (RV) walls (figure 9). Beyond these patchy areas of scar that 
tend to appear as dilation of the heart progresses in HF, there are other non-ischemic 
processes that can give rise to myocardial scar in other ways, summarized in figure 9. These 
include but are not limited to inflammatory and infectious cardiomyopathies such as 
sarcoidosis, viral myocarditis and Chaga’s disease. Furthermore, characteristic patterns of 
scarring can be seen in left ventricular hypertrophy (LVH) preceded by longer periods of 
increased load, such as in the presence of hypertension or valvular disease.  
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Figure 9. CMR-LGE: characteristic patterns of hyperenhancement of various 
cardiomyopathies 
 
Figure 9. Schematic overview of patterns of hyperenhancement on CMR images with late 
gadolinium enhancement (LGE) typically associated with various cardiomyopathies known to 
cause myocardial scar. Reproduced from Mahrholdt, et al.39, with permission. Abbreviations: 
HE – Hyperenhancement. 
1.4.2 Consequences 
 
Patients with myocardial scar as determined by CMR with late gadolinium enhancement 
(LGE) have poorer prognosis than those without, especially if the etiology of the scar is 
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ischemic41-45. There are several reasons for this, including but not limited to the mechanisms 
described below. 
1.4.2.1 Loss of cardiac function 
After cardiomyocytes undergo necrosis they are typically replaced by inelastic fibrous tissue, 
referred to as scar, consisting of fibroblasts and extracellular matrix comprised mostly of 
collagen39. Scar has different properties than normal myocardium in that scar tissue cannot 
conduct electrical signals well and cannot contribute to myocardial function, thereby leading 
to loss of contractile ability.  
1.4.2.2 Disruption of normal activation 
Beyond the loss of contractile ability due to loss of functioning cardiomyocytes, areas of 
myocardial scar may also disrupt normal electrical and mechanical activation patterns of the 
heart. This can lead to a suboptimal activation of the remaining viable myocytes in terms of 
the ability to optimally generate systolic function. Furthermore, inferior infarcts in particular 
may interfere with ability of the SA node to generate a regular rhythm and may also affect 
conduction over the AV node46. 
1.4.2.3 Arrhythmic substrate 
Electrophysiological studies have found that potentially deadly ventricular arrhythmias often 
originate from areas of myocardial scarring and can often be successfully prevented by 
ablation of remaining interspersed healthy cardiomyocytes in and around the scar tissue. 
These surviving cardiomyocytes can constitute a threat because they may get triggered into 
depolarizing at irregular intervals and by providing slow conducting pathways for re-entry 
phenomena to occur47. Moreover, a major cause of death early after a myocardial infarction is 
ventricular arrhythmias, with the highest risk occuring during the first few days after 
infarction46.  
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1.4.2.4 Decreased response to device therapy 
Cardiac resynchronization therapy (CRT) is a device therapy aimed at partially restoring a 
normal electrical activation pattern in patients with a dyssynchronous cardiac contraction48. 
Myocardial scar at the site of implantation of the LV lead tip has been shown to dramatically 
decrease the effectiveness of CRT48. 
1.4.3 Importance of diagnosis 
 
Presence and extent of myocardial scar may affect choice of treatment, particularly in 
patients with heart failure41, 45, 49. Increased scar extent heralds poor prognosis41, 44, 45, poor 
left ventricular ejection fraction (LVEF)50, increased risk of ventricular arrythmias47, 51 and 
poor response to CRT52-54. In addition, localization of myocardial scar affects prognosis in 
patients who receive CRT48, 52, 54. The clinical finding of myocardial scar may also warrant 
different secondary preventive treatment strategies depending on its cause. Different 
treatment strategies are prudent for a patient with a previous infarction versus a patient with 
myocardial scar due to myocarditis.  
1.4.3.1 Unrecognized myocardial scar is prevalent and dangerous 
Unrecognized myocardial infarction (MI) is common. One study found that among 599 
randomly selected Icelandic elderly participants (67-93 years of age) without diabetes, there 
were 54 (9%) who had a clinically recognized MI and another 85 (14%) who had 
previously unrecognized MI55. Corresponding numbers in 337 patients with diabetes were 
37 (11%) with recognized MI and another 72 (21%) with unrecognized MI55.  In addition, 
the patients with unrecognized MI were found to have less cardiac medication than patients 
with known MI, and a higher risk of death per unit of time with a hazard ratio (HR) of 1.45 
versus patients with no infarction, independently of age, gender and diabetes55. These 
numbers included only MI and did not take into account myocardial scar patterns consistent 
with non-ischemic etiology, which have been shown in other studies to be associated with 
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poor prognosis in patients with HF of non-ischemic etiology41, 45. In different study, n=1840 
somewhat younger US participants without a known history of coronary artery disease 
(CAD) underwent CMR at ten years after baseline (mean age 69 at CMR)56. The study 
found that non-ischemic scar was as prevalent as ischemic scar (4.1% and 3.8% prevalence, 
respectively).  
1.4.3.2 Impact of scar on response to device therapies 
Several studies have found that scar burden estimated either by CMR LGE49, SPECT-
estimated perfusion defect57 or ECG58-60 is associated with poor response to CRT. The aim of 
CRT is to resynchronize the heart’s walls when a conduction abnormality causes mechanical 
dyssynchrony. Already in 1968, adverse effects of abnormal activation induced by RV apical 
pacing were found by Kowolsky et al12. The activation sequence of the LV during RV pacing 
share similarities the pattern in LBBB61. The results is a delayed activation of the lateral wall 
of the LV, which causes dyssynchrony visible in functional cardiac imaging, e.g. by CMR as 
shown in figure 7, panel C. This dyssynchrony is partially corrected in CRT by insertion of 
two ventricular pacing electrodes, one in the traditional RV apical position and another in the 
LV lateral wall62, resulting in a more synchronous LV activation as shown in figure 10. 
Therefore, when there is scar in the LV lateral wall at the site where the LV pacing electrode 
lead tip is implanted, the scar may act as an insulator and prevent myocardial depolarization 
from following a pacing impulse54. Therefore, both scar burden and localization may impact 
CRT response.  
Recently, the alternative option of His bundle pacing has been gaining ground as a means to 
utilize the existing Purkinje fiber network to restore the natural multisite activation sequence. 
This technique is currently being explored and the procedural details are being refined. His 
bundle pacing often reverses the distinct ECG appearance of LBBB completely, indicating 
that the block can often be overcome to employ the existing Purkinje network to a great 
extent63. In addition, a recent study has shown that patients with LBBB and mild HF 
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symptoms have a higher risk of heart disease28, suggesting the importance of avoiding 
extended time periods of stress on the heart induced by a suboptimal activation sequence. 
This notion is also supported by the finding of adverse effect on myocardial function after 
long durations of RV pacing64. One study has shown that the combination of His bundle 
pacing and traditional CRT has favorable hemodynamic properties over CRT alone, 
demonstrating that it is beneficial to even partly recruit the native Purkinje network65. 
Finally, presence and extent of myocardial scar has been shown to predict who benefits from 
treatment with implantable cardioverter defibrillator (ICD)51, 66. This finding is in line with 
the concept of myocardial scar as an arrhythmogenic substrate described above. 
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Figure 10. Endocardial mapping of activation sequence during LBBB with and without 
biventricular pacing.
 
Figure 10. The decreased delay in activation of the lateral wall during biventricular pacing 
is visualized by endocardial mapping, showing activation sequence in representative canine 
hearts with LBBB. Areas of same color are activated near simultaneously (isochrones), at the 
time from start of activation indicated by the color-scale to the right. Abbreviations: LBBB – 
Left bundle branch block. BiV pacing – biventricular pacing. ms – milliseconds. Reproduced 
and adapted from Rademakers, et al.67, with permission. 
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1.5 DETECTION OF MYOCARDIAL SCAR 
 
There are multiple methods aimed at detecting the presence, causes and consequences of 
myocardial scar. All of these methods have particular roles to play in clinical routine care. 
The most commonly used methods are summarized in this section, apart from the ECG which 
is described in greater detail later in this thesis. 
1.5.1 Cardiovascular magnetic resonance imaging with late gadolinium 
enhancement 
 
Magnetic resonance imaging (MRI) utilizes the effect of strong and rapidly changing 
magnetic fields upon the spinning of hydrogen nuclei in the body, and is generally an 
excellent method to image soft tissues. The main advantage of the method is highly accurate 
imaging without need for ionizing radiation. However, MRI is relatively costly and requires 
specially trained operators to ensure high image quality and patient safety. The MRI scanner 
can acquire images with many different properties using various pulse sequences. These are 
preprogrammed descriptions detailing timing, magnitude and spatial direction of changes in 
magnetic fields and radio frequency pulses, as well as timing of data acquisition. The 
preferred category of pulse sequences to image myocardial scar are referred to as LGE or 
delayed enhancement (DE) sequences, during which data is acquired 10-15 minutes after 
administration of a gadolinium-based contrast agent68, 69. The rationale for this is that 
intravenously administered gadolinium-based contrast agents distribute into the body’s 
extracellular space but do not enter living cells. Because areas of myocardial scar consist of 
large amounts of collagen interspersed with small and elongated fibroblasts, myocardial scar 
has a much higher proportion of extracellular volume fraction68, 70. As a consequence, 
contrast is found in higher concentration in areas with myocardial scar compared to healthy 
myocardium. Gadolinium heavily influences the magnetic property T1 of a given tissue, 
which is the rate at which a proton returns to its their original spinning direction in the 
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magnetic field of the scanner after having been temporarily influenced by a radio frequency 
pulse. Therefore, images where signal intensity is primarily influenced by T1 can be used to 
differentiate areas with high and low extracellular volume fractions such as scar and 
myocardium. An example of an LGE image is shown in figure 11. 
Figure 11. CMR-LGE images from a patient in study V with a transmural inferior 
infarction.
 
Figure 11. The left panel is short axis CMR-LGE image from a patient in study V with 
evidence of transmural infarction in the inferior wall (white arrows), clearly distinguishable 
from the dark healthy myocardium. The right panel is a long axis 2-chamber view in which 
the presence of white hyperenhancement can be confirmed in the inferior wall (white 
arrows). The dashed lines show where the respective image planes of the left and right panels 
intersect. 
1.5.2 Echocardiography 
Echocardiography cannot be used to directly differentiate between myocardial scar and 
healthy myocardium but can still detect typical functional and morphologic changes 
associated particularly with ischemic scar. Myocardial infarctions typically result in marked 
wall thinning (as is visible in figure 11). Furthermore, Tissue Doppler based echocardiograpic 
parameters can be used as a quantitative way of differentiating between non-contractile 
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myocardial scar and healthy myocardium by assessing wall motion71. Echocardiography 
requires less expensive equipment than CMR, is less cumbersome and similarly to CMR does 
not entail exposure to ionizing radiation. However, echocardiography does not allow tissue 
characterization with the same accuracy as CMR and is more dependent on a skilled observer 
to reproducibly interpret images71.  
1.5.3 Myocardial scintigraphy 
Single photon emission computed tomography (SPECT), also known as myocardial 
scintigraphy, involves injecting a radioactive tracer into the bloodstream. The tracer is taken 
up by tissue in proportion to both mitochondrial content and perfusion, and the radiation from 
the tracer is subsequently detected to produce tomographic images. The advantage of the 
method is the ability to map out the relative perfusion within the heart during rest, exercise or 
pharmacological stress. Consequently, myocardial scintigraphy is unable to identify areas 
with non-ischemic scar as well as areas of scar with restored perfusion. However, the 
technique is highly useful in determining whether coronary artery stenosis is present without 
need for invasive catheterization. Still, some studies use resting SPECT as a reference 
standard identifying myocardial scar57.  
1.5.4 Coronary angiography 
Coronary angiography involves inserting intraarterial catheters and manipulating them to 
reach the coronary arteries. The procedure is not without risk, but has great diagnostic and 
therapeutic utility in detecting and opening up stenoses in coronary arteries. In order to 
visualize the blood vessels during the procedure, a contrast agent is injected as moving x-ray 
images are obtained (fluoroscopy). 
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1.5.5 Computed tomography 
 
Cardiac computed tomography (CT) can be performed using late enhancement imaging with 
iodinated contrast agents. The same basic technique of performing imaging between 5-15 
minutes after administration of contrast is employed for both CT and CMR. Myocardial scar 
identified by cardiac CT correlates well with both CMR-LGE and pathology72-75. However, 
the contrast to noise ratio for myocardial scar by late enhancement CT is far lower than for 
CMR, thus rendering late enhancement CT less useful in clinical routine. 
1.5.6 Post mortem examination 
 
Histologic and/or macroscopic examination of hearts from deceased patients can reveal areas 
of myocardial scar by applying tetraphenyl tetrazolium chloride (TTC) dye76. Application of 
TTC results in macroscopically clearly visible myocardial scar which allows for rigorous 
validation of novel techniques to image myocardial scar. It has been demonstrated the CMR-
LGE images correlate well with infarcted areas by post mortem examination with TTC68. 
1.6  ELECTROCARDIOGRAPHIC DIAGNOSIS OF CHRONIC MYOCARDIAL 
SCAR 
 
The 12-lead ECG is a highly useful method to detect acute ischemia by assessment of 
repolarization disturbances visualized in the ST segment (as shown in figure 12). The ECG 
can also in many cases detect past myocardial infarction and other types of myocardial scar, 
which is the focus of this thesis. Using the standard 12-lead ECG, localized loss of 
electrical forces due to infarction can be visualized. In the absence of conduction 
abnormalities, this loss of activation typically manifests as pathological Q-waves as shown 
in figure 13 and loss of R-wave amplitude in certain leads depending on the localization of 
the diseased myocardium. These observations have been made in many different studies, 
which has resulted in a wide array of ECG criteria for myocardial scar. One attempt at 
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consolidating ECG criteria for a wide range of diseases is the Minnesota code77. Another is 
a series of attempts at standardizing ECG interpretation through a series of publications by 
the AHA18, 78-82. Perhaps because the ECG has been around for so long as a common 
diagnostic method, there are many misconceptions around the connections between certain 
ECG patterns and the properties and presence of myocardial scar among doctors and health 
professionals world wide. One such misconception is that the ECG can reliably 
discriminate between transmural and subendocardial infarctions by the presence or absence 
of Q-waves (figure 13). A recent study comparing ECG and CMR found that pathological 
Q-waves appear in 8% of patients without MI, in 50% of patients with subendocardial 
infarction and 72% with transmural infarction83. A different ECG analysis method that 
focuses solely on detection of chronic myocardial scar is the Selvester QRS score described 
below. 
Figure 12. ECG with ST-elevation induced by acute myocardial ischemia 
 
Figure 12. The figure shows the typical ECG sign of acute myocardial ischemia 
threatening imminent myocardial infarction. The T-wave (yellow square) starts 
immediately after the QRS-complex high above the baseline, making the QRS-complex and 
T-wave hard to separate. In a healthy patient, the ST-segment between the QRS-complex 
and the T-wave is normally flat and in level with the baseline as shown in figure 1. 
Furthermore, the absence of the normally present R-wave in lead V2 indicates a loss of 
depolarizing myocardium in the anteroseptal wall. Figure is public domain and can be 
reproduced for any purpose without permission. 
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In addition, pathological processes that lead to myocardial scarring may affect the conduction 
system and the pacemaker function of the heart. These effects include RBBB caused by 
septal infarction27 and impairment of AV- or SA-node function typically caused by right 
coronary artery occlusion46. 
 
Figure 13. Schematic illustration of Q-waves 
                                              
Figure 13. A Q-wave is a negative deflection at the start of the QRS-complex. In most 
leads, the QRS-complex normally starts with a positive deflection as in the normal ECG 
shown in figure 1. Myocardial infarction and other pathological processes can lead to 
localized loss of healthy myocardium, which in turn decreases spread of depolarization in 
certain directions. This may in turn cause decreased R-wave amplitude or even appearance 
of abnormal Q-waves in certain leads relative to localization of the lost myocardium. In 
general, deeper and wider Q-waves are thought to indicate greater loss of healthy 
myocardium. Figure reproduced from Loring, et al.,84 with permission. 
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1.7 SELVESTER QRS SCORE 
1.7.1 Original Development 
 
The Selvester QRS score is an ECG scoring method that aims to detect, quantify and 
localize myocardial scar through analysis of QRS complex morphology30. The original 
version of it was developed in the 1970’s based on computer simulations that were in turn 
based on the pioneering experiments by Durrer et al described above15, 85-92. The Selvester 
QRS score was designed to only be used in the absence of conduction abnormalities that 
change the appearance of the ECG such as LBBB, right bundle branch block (RBBB), left 
anterior fascicular block (LAFB) and electrocardiographic LVH30. The basic method of 
developing the Selvester QRS score was careful study of the impact on myocardial scar in 
different regions of the heart upon the ECG appearance in computer simulations, which 
Selvester then used to construct ECG criteria for presence of myocardial scar30. Next, these 
ECG criteria were consolidated into a unified scoring system. The more criteria a patient 
met, the larger the myocardial scar was hypothesized to be. Selvester also sought to make 
predictions about scar location and size by translating the specific criteria into points. These 
points were in turn translated into certain quantities of scar distributed into twelve 
myocardial regions, as shown in figure 14. Over the next decades, the criteria comprising 
the Selvester QRS score were evaluated against myocardial scar found and quantified 
during post mortem pathologic examinations. During this process, the criteria were 
incrementally refined to improve diagnostic performance. A limitation with this method 
was the amount of work involved in each post-mortem examination, which limited the size 
of datasets in which the Selvester QRS score could be refined and validated. Another 
limitation was that additional infarction could theoretically have developed in some patients 
in between the last available 12-lead ECG and the time of death. Later comparison during 
the 2000’s between anterior infarct size by Selvester QRS scoring and by CMR-LGE93 
showed a modest correlation between the two methods (r=0.40). Although it was for a time 
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one of the easiest, most accessible and accurate ways to non-invasively image myocardial 
scar, the Selvester QRS score never achieved widespread clinical use. One reason for this 
may be the relatively cumbersome application, with need for careful measurements of a 
multitude of ECG waveforms, followed by calculation of the overall score. Efforts to 
automate the score have been made94 but have not been widely implemented. Another 
reason why the Selvester QRS score never became widely used may be because perceived 
lack of incremental clinical utility beyond the classical signs of chronic MI in the 
Minnesota code, such as pathological Q-waves. 
1.7.2 Adaptation for conduction abnormality 
 
Despite the limitations described above, the prospect of identifying, quantifying and 
localizing myocardial scar using the ECG saw new interest late in the first decade of the 
2000’s as it became apparent that scar had a role in the 30% non-response rate to CRT31, 62, 
95-97. The ECG was found to be a key predictive method and it soon became clear that 
patients with LBBB were the group with highest response rate96, 98. Thus, Selvester and 
Strauss adapted the Selvester QRS score for use in the presence of various conduction 
abnormalities. The new adapted versions of the Selvester QRS score were published in 
200930 and were designed to take into account the altered myocardial activation pattern in 
the presence of the following conduction abnormalities: LBBB, RBBB, LAFB, LVH and 
the combination of RBBB+LAFB. The LBBB version is shown in figure 15 and the other 
conduction types are shown in figure 14. Prior to the work described in this thesis, these 
versions had only been initially validated against CMR-LGE in small populations, although 
with promising results99. Further, the Selvester QRS score was shown to be predictive of 
echocardiographic CRT-response58, which was later corroborated59. Successful efforts were 
therefore made to automate the 2009 LBBB version of the Selvester QRS score (2009 
LBSS)100, 101, in parallel to its thorough evaluation against CMR-LGE. 
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Figure 14. The 2009 Selvester QRS score, adapted for conduction abnormalities. 
Figure 14. The table to the left shows which set of QRS-morphology criteria is intended for 
which conduction type. Each score point translates into scar equivalent to roughly 3% of 
the LV mass, distributed within the LV according to the table in the middle. The right hand 
panel provides further instruction for the application of the Selvester QRS score. Criteria 
differing from the normal conduction Selvester QRS score are highlighted. Figure 
reproduced from Strauss, et al.,30 with permission. 
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Figure 15. The 2009 Selvester QRS score adapted for left bundle branch block 
 
Figure 15. The table to the left in the image shows the individual QRS-morphology criteria 
and their translation into points. Each point represents presence of scar roughly equivalent 
to 3% of the left ventricular mass. Further, each point is divided into one of five myocardial 
regions: four equiangular quadrants and the apex, as visualized in the middle section of the 
figure. The right panel contains instructions for the application of the score. Figure 
reproduced from Strauss, et al.,30 with permission. 
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2 AIM 
 
The aim of this thesis was to investigate the ability of the 2009 Selvester QRS score to 
detect, quantify and localize myocardial scar in LBBB, RBBB, LAFB and RBBB+LAFB, 
with special emphasis on LBBB due to its importance in clinical decision-making regarding 
CRT. A secondary objective was to modify the Selvester QRS score to optimize 
electrocardiographic characterization of myocardial scar in the presence of LBBB. 
 
The aims of each specific study were: 
I) To determine the ability of the component criteria of the 2009 LBBB version of 
the Selvester QRS score (2009 LBSS) to localize myocardial scar into five 
myocardial wall regions. 
II) To evaluate the performance of the 2009 Selvester QRS score to detect and 
quantify myocardial scar in four conduction abnormalitites: LBBB, RBBB, 
LAFB and the combination of RBBB+LAFB. 
III) To measure the specificity of each of the component criteria of the 2009 LBSS 
in a population of patients with no scar verified by CMR.  
IV) To determine the prognostic utility of Selvester QRS scoring in patients of 
various conduction types with or without CRT as an addition to ICD in the 
Multicenter Automated Defibrillator Implantation Trial – Cardiac 
Resynchronization therapy (MADIT-CRT) population. 
V) To revise the 2009 LBSS through comparison of continuous ECG variables to 
CMR-identified myocardial scar presence and extent in a large multicenter 
dataset of patients with LBBB. 
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3 MATERIALS AND METHODS 
3.1 STUDY POPULATIONS 
 
The study population for study I consisted of the LBBB subgroup (n=39) of a cohort of 235 
consecutive patients referred for ICD implantation at Johns Hopkins University Hospital, 
Baltimore, MD, USA66, and did not overlap with the other studies in this thesis. Study IV was 
a substudy conducted in the large multicenter MADIT-CRT population31, which did not 
overlap with the study populations from study I, II, III and V. 
The study populations for study II, III and V partially overlapped and were composed of 
retrospectively identified patients that had LBBB, RBBB, LAFB or RBBB+LAFB 
determined by an ECG recorded close in time to a CMR scan at one of four centers: 
Karolinska University Hospital, Stockholm, Sweden; Skåne University Hospital, Lund, 
Sweden; Duke University Medical Center, Durham, NC, USA or University of Pittsburgh 
Medical Center, Pittsburgh, PA, USA. Study II was performed on consecutive patients at 
Duke University Medical Center who underwent CMR between January 2011 and August 
2013 and had either one of the four conduction abnormalities LBBB, RBBB, LAFB or the 
combination of RBBB+LAFB by ECG. Study III included patients with no scar by CMR 
from Karolinska, Lund and Duke. Study V included all Karolinska patients from study III, 
the LBBB subgroup of the study population in study II and additional LBBB patients from all 
four centers mentioned above.  
3.1.1 Study I 
 
The study was conducted as a substudy of the LBBB subgroup of a prospectively enrolled 
cohort of patients referred for ICD with LVEF ≤35%. Enrollment took place at Johns 
Hopkins University Hospital during the period between November of 2003 and December 
2010. Out of 235 patients in the cohort, 45 were identified as having LBBB by the Strauss 
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criteria described above. After two patients were excluded due to insufficient ECG quality, 
one for incomplete CMR coverage of the LV, and another three due to small scar the 
remaining 39 patients constituted the study population. Patients with small CMR scar were 
excluded in order to create clearly scar positive or scar negative groups in which to measure 
sensitivity and specificity of ECG criteria for scar in different areas of the LV. 
Exclusion criteria during enrollment are described in full in a previous publication by the 
authors of the original prospective study47 and were among others NYHA functional class IV, 
acute myocarditis, arrhythmic ICD indication, hypertrophic cardiomyopathy and congenital 
or storage heart disease. Furthermore, patients with creatinine-estimated clearance of < 30 ml 
per minute were excluded starting with patients enrolled in 2006. The year 2006 marked the 
discovery that such patients were at a small risk of developing nephrogenic systemic fibrosis 
following administration of gadolinium-based contrast agents102. 
All patients provided written informed consent to participate in the original prospective 
study47. The institutional review boards (IRB) at Duke University and Johns Hopkins 
University Hospital as well as the US Food and Drug administration (FDA) human research 
committee approved the study protocol for the substudy. 
3.1.2 Study II 
 
Study II was conducted using a retrospectively identified dataset consisting of all patients 
who underwent a clinically motivated CMR scan at Duke University Medical Center between 
August 2011 and January 2013 that had ECG evidence of either LBBB, RBBB, LAFB or the 
combination of RBBB+LAFB. Exclusion criteria were poor CMR image quality and poor 
quality ECG. The study protocol was approved by the Duke University IRB. Sample size, 
cohort characteristics and distribution according to conduction type is shown in table 2. 
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Table 2. Cohort characteristics of Study II population. 
 
Table reproduced from Study II, with permission. 
3.1.3 Study III 
 
A total of 99 patients who had ECG evidence of LBBB by the Strauss criteria19 and no 
myocardial scar were retrospectively identified from the clinical CMR databases at three 
centers: Duke University Medical Center, Karolinska University Hospital and Skåne 
University Hospital, Lund, Sweden. Inclusion criteria were ECG registration at the latest 30 
days after CMR scan, acceptable quality CMR-LGE images to rule out myocardial scar and 
and sufficient quality ECG recording for application of the Selvester QRS score. The study 
population partially overlapped with that of study II, in that patients with LBBB and no scar 
were also included in study III. In addition, patients having undergone CMR at Karolinska 
University Hospital between 2003 and 2014 and at Lund from 2011 through 2014 were 
screened for participation. In order to identify patients who met inclusion criteria, the clinical 
CMR databases were compared against the clinical ECG databases to select patients with 
automatically detected LBBB. The resulting identified ECGs were then reviewed manually in 
order to include one ECG per patient that met Strauss criteria for LBBB that also had the 
highest quality and was closest in time to the CMR scan. The respective ethical committees at 
all three centers approved the study protocol. Furthermore, patients either provided written 
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informed consent or the requirement for written consent was retrospectively waived by the 
respective ethical committee or IRB. 
3.1.4 Study IV 
 
The fourth study was a substudy of the 1820 patients included in the prospective MADIT-
CRT population31, in which patients were randomized in a 2:3 fashion to either implantation 
of ICD alone or implantation of a combined CRT and ICD device (CRT-D). Inclusion criteria 
are described in detail in the original MADIT-CRT protocol103 and were in summary: >21 
years of age, ischemic (NYHA I-II) or non-ischemic (NYHA II only) cardiomyopathy and a 
QRS duration of >130 ms. Exclusion criteria included existing indication for either CRT or 
ICD according to criteria at enrollment, previously implanted CRT or ICD, coronary artery 
bypass graft (CABG) operation. A more detailed description of the study protocol is 
previously published103. This study population did not overlap with any of the other studies in 
this thesis.  
3.1.5 Study V  
 
Study V included patients with an available digital ECG and who had undergone a CMR scan 
for any reason at one of four centers: Pittsburgh University Medical Center, Duke University 
Medical Center, Karolinska University Hospital, Stockholm, Sweden and Skåne University 
Hospital, Lund. For three centers (Duke, Pittsburgh and Karolinska), clinical CMR databases 
were compared to the clinical ECG databases in order to screen for patients who met the 
Strauss criteria for LBBB and who had a good quality ECG recorded close in time to the 
CMR scan (<30 days, unless the ECG was recorded prior to CMR, in which case no time 
limit was required). The Lund patients were the LBBB subgroup from a separate ongoing 
prospective study that met the inclusion criteria of study V and had evidence of scar by CMR. 
Patients were excluded if either the ECG or CMR was of poor quality or if they had CMR 
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evidence of congenital heart disease, myectomy or infiltrative heart disease. The study 
population for study V included the Karolinska and Duke contingents of Study III and most 
of the patients with LBBB and myocardial scar from study II. Patients either provided written 
informed consent, or alternatively, the requirement for informed consent was waived 
retrospectively by the respective IRB or ethical committee. Approval was obtained from the 
IRB or ethical committee at each respective center.  
 
 
3.2 ECG ACQUISITION AND ANALYSIS 
 
Standard 12-lead ECGs were recorded under clinical conditions using clinical ECG machines 
from three different vendors, depending on center and time period, with the majority of the 
ECGs being recorded on a GE Marquette system (General Electric, Little Chalfront, UK). 
Other ECGs were recorded on either a Siemens system (Siemens, Erlangen, Germany) or a 
Philips system (Philips, Best, the Netherlands). Paper ECGs were printed out and deidentified 
for manual application of Selvester QRS scoring.  For study V, digital ECGs were exported 
and digitally anonymized at each respective center.  
3.2.1 Classification of conduction type 
For studies concerning only LBBB or LBBB versus non-LBBB (studies I, III, IV and V) 
ECGs were classified as LBBB if they met Strauss criteria for LBBB19: ≥130 ms QRS 
duration (≥140 ms for men), rS or QS configuration in lead V1 and presence of mid-QRS 
notching or slurring in ≥ of leads I, aVL, V1, V2, V5 and V6. In study II, ECGs were 
classified into the following conduction types: LBBB, RBBB, LAFB, RBBB+LAFB or 
normal conduction in accordance with a previously published guide to the application of 
Selvester QRS scoring84.  
 38 
3.2.2 Application of the Selvester QRS score 
 
Selvester QRS scoring was performed in accordance with a previously published guide84 
containing detailed definition of each waveform in the respective context of each of the 
individual component criteria listed in figures 14 and 15. Selvester scoring was performed by 
a single observer in studies I and IV. In study IV, a subset of ECGs flagged as difficult were 
also reviewed and adjudicated by a second observer. In studies II and III, Selvester QRS 
scoring was performed by two independent observers with disagreements being adjudicated 
in conference. For study V, continuous waveform measurements were obtained using a 
dedicated software, and these measurements were then used to calculate the Selvester QRS 
score.  
3.2.3 Development of ECG analysis software 
 
We developed a custom ECG analysis software in order to obtain detailed continuous ECG 
measurements. Software development was performed through an iterative process of user 
feedback and subsequent modifications, with all programming being performed by Xiaojuan 
Xia at Rochester University, New York, USA.  
3.2.4 Continuous measurement on digital ECG recordings 
The software allowed a stepwise measurement of both global and lead-by-lead QRS complex 
waveform metrics. The measurement process is summarized in figure 16. Global 
measurements were obtained by placement of fiducial markers on superimposed QRS median 
complexes of all 12 leads at QRS onset and offsets, as well as at the estimated start, peak and 
end of the LBBB notch required by the Strauss LBBB criteria. On a lead-by-lead basis, 
fiducial markers were placed whenever the signal crossed above or below the PQ-baseline, as 
well as at the peak of each waveform. Thus, the timing of the start, end and peak/nadir of Q, 
R, S, R’, S’, R’’, S’’ and so forth could be computed, as well as the maximum or minimum 
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amplitude of each waveform and the maximum and minimum amplitude of the overall QRS 
complex in each lead. In addition, the timing and amplitude of the start, end and peak/nadir of 
each notch and slur was recorded according to definitions in figure 16. As a rule, each slur or 
notch had to be judged to visually be of greater magnitude than background noise, which 
introduced a limited degree of subjectivity into the analysis.  
Figure 16. Summary ECG measurement procedure in Study V 
Figure 16. This figure shows a summary of how continuous measurements were obtained 
from the digital ECGs in study V. First, fiducial markers were placed at the QRS on- and 
offset in a global view with median complexes of all superimposed (Panel A). Further, 
fiducial markers were placed at the visually estimated start and end of the mid-QRS notch or 
slur mandated by the Strauss criteria for LBBB19. Next, lead-by-lead waveform 
measurements were obtained as shown in Panel B by placing fiducial markers at the start, 
peak/nadir and end of each waveform. In addition, the timing and amplitude of the start and 
end of notches and slurs were recorded, as well as of the peak/nadir of notches in every lead. 
Panel C shows a schematic illustration of the working definitions of notch and slur 
measurements. Notches and slurs were disregarded if visually indistinguishable from 
baseline noise. Figure reproduced from Study V manuscript. 
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3.3 CMR ACQUISITION AND ANALYSIS 
 
The specifics of both scanners, coils, pulse sequences and contrast agents varied across 
centers and periods of time during which CMR scans were carried out. The CMR images 
were acquired at five centers: Johns Hopkins University Hospital (Study I), Duke University 
Medical Center (Studies II, III and V), Karolinska University Hospital (Studies III and V), 
Skåne University Hospital, Lund (Studies III and V) and University of Pittsburgh Medical 
Center (Study V). Both 1.5 T and 3.0 T scanners were used from multiple vendors. The 1.5 T 
scanners included: GE Signa CV/i (GE, Little Chalfront, UK); Philips Intera (Philips, Best, 
the Netherlands); Siemens Magnetom Espree, Aera and Avanto (Siemens, Erlangen, 
Germany). The 3.0 T scanners were: Philips Intera (Philips, Best, the Netherlands) and 
Siemens Verio (Siemens, Erlangen, Germany). Phased array cardiac receiver coils and 
ECG gating were used for all image acquisition. Specific contrast agents included: 
Gadoversetamide, Mallinkrodt Inc, St. Louis, MO, USA; gadoteridol, Prohance, Bracco 
Diagnostics, Monroe Township, NJ, USA; gadoteric acid, Guerbet, Gothia Medical AB, 
Billdal, Sweden and Gadoterate meglumine, Guerbet LLC, Bloomington, IN, USA). At all 
centers, viability imaging was performed using various LGE pulse sequences. These 
involved inversion recovery images with our without motion correction acquired typically 
10-15 minutes after administration of 0.10-0.15 mmol per kg of bodyweight of one of the 
gadolinium-based contrast agents described above. Voxel dimensions varied with the field 
of view demanded by patient size, but were typically varied between 1.42-1.82 mm2 in plane 
resolution, 6-8 mm slice thickness and a 0-4 mm interslice gap. 
Cine images for study V were typically acquired using a steady-state free precession 
protocol prior to administration of contrast. Typical in plane resolution was close to 1.5x1.5 
mm2 with a slice thickness and interslice gap of 6 mm and 4 mm, respectively. The typical 
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temporal resolution was between 25-40 frames per second, depending on protocol and heart 
rate. In general, 20-25 frames were recorded for one cardiac cycle.  
3.3.1 CMR export and anonymization 
For study V in which CMR images were exported and compiled into a dataset, CMR images 
were anonymized at each respective center. LGE images were exported for all patients. Cine 
images were inluded with matching slice positions whenever available. The local radiological 
information system (RIS) and Picture archiving and communications system (PACS) was 
accessed on-site at the four participating centers in study V. Next, images were exported to a 
local work station in standard Digital imaging and communications in medicine (DICOM) 
format. Images were then loaded into a locally installed version of the image analysis 
software Segment (Medviso, Lund, Sweden)104, 105. Subsequently, each patient was provided 
with a subject ID recorded into a local digital subject identifier key kept in computers within 
the local firewall of each respective center. Images were anonymized and exported as 
MATLAB formatted data (file extension “.mat”), after which anonymized images were 
stored and analyzed on a personal computer.  
3.3.2 Analysis of late gadolinium enhancement images 
 
Analysis of LGE images was performed differently for the different studies. In all studies, the 
presence of scar was visually determined and then confirmed in two consecutive or 
orthogonal slices. In study I, CMR scar was quantified as described previously47 by manual 
delineation of visually determined scar borders and endo- and epicardial borders. The pixels 
within the area outlined as scar were divided into core scar (>50% of the maximal signal 
intensity within scar), gray zone scar47 and healthy myocardium. Gray zone pixels were 
defined as having a signal intensity greater the peak signal intensity of a remote region of 
interest in healthy myocardium but lower signal intensity than core scar47. In study II, scar 
was visually quantified by dividing the LV into segments and then grading scar transmurality 
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in each segment as 0-4 with steps 1-4 corresponding to 25% transmurality incremental 
intervals. The subdivision model used was the 17-segment model shown in figure 17, 
endorsed by the AHA106. Next, the percentage of LV mass consisting of scar tissue was 
estimated by assuming that all 17 segments have equal mass and by approximating scar 
transmurality in each segment as the midpoint of the transmurality interval stipulated by each 
category. As an example, if a certain segment is thought to have a scar transmurality of 50-
75%, it is assigned category 3. That segment is thus thought to contain scar mass equivalent 
to (50+75%)/2/17 = 3.7 % of the total LV mass. When every segment is summed up this way, 
an overall scar percentage of LV mass is yielded.   
Figure 17. Polar plot of the AHA17 LV subdivision model  
 
Figure 17. The AHA 17-segment subdivision model displayed as a polar plot106. The left 
ventricle is depicted as a hemisphere viewed from below, with the middle circle representing 
the apex and concentric layers representing incrementally more basal myocardial wall 
regions. Figure reproduced from Cerqueira et al106 with permission. 
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For study V, presence of scar was visually determined by identification of LGE in either two 
consecutive short axis (SA) slices or in two orthogonal views. Scar was categorized as 
ischemic if areas with LGE were either subendocardial or transmural and approximately 
respected coronary artery distribution territories, as shown in figure 18. Patients with 
ambiguous scar etiology or borderline image quality were adjudicated by a second 
experienced observer. Scar was quantified using the appropriate semi-automatic algorithm in 
the software Segment (Medviso, Lund, Sweden)104, 105, depending on whether LGE image 
inversion recovery type was either a phase sensitive (PSIR) or magnitude (MAGIR) 
reconstruction. The manual part of the scar quantification process in Segment involves 
delineation of endo- and epicardial borders for every slice covering the LV in a SA-stack as 
well as manual correction of erroneous scar detection due to artifacts.  
Figure 18. The distribution of the AHA17 segments into coronary artery territories. 
 
Figure 18. This figure shows how the AHA17 segments are approximated into the coronary 
artery territories. Abbreviations: LAD - left anterior descending artery. RCA – Right 
coronary artery. LCX – left circumflex artery. Figure adapted from Cerqueira et al106 with 
permission. 
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All images were analyzed either by a single observer or by one observer performing 
delineation and second observer adjudicating the sometimes challenging delineation as well 
as performing manual corrections of automated scar quantification. The end output provided 
by the Segment software is global scar extent expressed as percentage of LV mass, as well as 
localized scar expressed as percent of each AHA17 segment, which is shown in figure 17. 
3.3.3 Measurement of dimensions and function 
 
Measurement of LVEF, LV mass (LVM) and end diastolic volume (EDV) were obtained 
from measurements performed on cine images either as part of clinical reports at each local 
center or as research measurements performed in Segment (Medviso, Lund, Sweden)104, 105, 
107, 108. In Segment, the time frames representing end diastole (ED) and end systole (ES) were 
determined visually using both long axis (LA) images and a midventricular SA image. Next, 
endo- and epicardial borders were outlined in both ED and ES in the entire SA stack. LV 
function, expressed as LVEF, and LV dimensions, expressed as LVM and EDV, were then 
calculated in Segment based on known voxel dimensions and interslice gap. In addition, 
LVM and EDV were indexed (LVMI and EDVI) to body surface area (BSA) estimated from 
height and weight using the Dubois formula109.  
 
3.4 ECHOCARDIOGRAPHIC ANALYSIS 
 
Echocardiographic analysis was performed at baseline and at 1-year follow-up in study IV at 
each respective center participating in the MADIT-CRT trial. Echocardiographic LVEF and 
EDV were computed using the Simpson model of discs as recommended by guidelines110. 
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3.5 STATISTICAL ANALYSIS 
 
Continuous background variables were reported as mean ± standard deviation (SD), with 
selected variables reported as median and range or interquartile range (IQR). In study V, 
normality of distribution was tested for using the Kolmogorov-Smirnov (K-S) test. Variables 
found to deviate significantly from normal in their distribution were reported in study V as 
median and IQR. Categorical variables were reported as absolute numbers and proportions.  
Differences in means between two groups were tested for with the unpaired Students t-test. In 
cases with multiple groups, differences in means were tested for using analysis of variance 
(ANOVA) test. Correspondingly, differences in medians were tested for using Mann-
Whitney U test or Kruskal-Wallis test, as appropriate. Differences in proportions were 
determined by Pearson’s chi squared test. Ninety-five percent confidence intervals (95% CI) 
for means were estimated as the mean±1.96 times the standard error of means (SEM). For 
proportions, binomial 95% CIs were computed using the exact method. Cox proportional 
hazards were used to calculate hazard ratios (HR) for survival analysis. Linear correlations 
between continuous variables, such as myocardial scar estimated by both Selvester QRS 
scoring and CMR, were estimated using linear regression. In study II, agreement between 
continuous measurements was reported as intraclass correlation coefficient (ICC). 
Correlations between continuous predictor variables and binary outcomes were estimated 
using logistic regression. Performance of diagnostic tests was reported as specificity, 
sensitivity and area under the curve (AUC) derived from receiver operating characteristic 
(ROC) curves as well as intraclass correlation coefficient (ICC). Differences in AUCs were 
tested for using a previously described method111. In study I, a modified forward stepwise 
regression analysis approach was employed to identify the subset of 2009 LBSS criteria 
achieved best performance in diagnosing myocardial scar in a given myocardial wall region.
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4 RESULTS AND DISCUSSION 
 
Studies I-III concerned the performance of the 2009 LBSS versus CMR-LGE in detecting, 
quantifying and localizing myocardial scar. In study IV, the clinical utility of Selvester QRS 
scoring in predicting clinical benefit of CRT-D over ICD treatment only was investigated. 
Study V focused on revising and improving the 2009 LBSS.  
4.1 LOCALIZATION OF MYOCARDIAL SCAR USING THE 2009 LBSS 
CRITERIA: STUDY I 
 
Prior to the commencement of the study, high scar burden and lateral scar were both known 
to be associated with poor response to CRT52, 54. Simultaneously, a situation in HF care had 
evolved in which expensive CRT devices with potentially unwanted side effects were 
implanted in many patients with a non-response rate of approximately 30%31. Even though 
myocardial scar was thought to be a key factor in determining CRT appropriateness, 
performing a CMR scan on every candidate for CRT was not a widely adopted strategy due 
to restricted availability. Therefore, we addressed the prospect of using the inexpensive and 
widely available 12-lead ECG to screen for and localize myocardial scar as a simple strategy 
toward more targeted and individualized HF treatment.  
The 2009 LBSS had not taken any empirical data into account during its construction but was 
purely a creation from theoretical model of conduction in LBBB (partially shown in figure 7, 
panel A). Still, each criterion was postulated to predict scar in one of five myocardial wall 
regions, as shown in figure 15. It thus appeared to be reasonable to expect a wide 
heterogeneity in diagnostic performance among the criteria. We therefore sought to identify 
the best performing combination of criteria to detect myocardial scar in each respective 
myocardial wall region. Because of a limited dataset (n=39 patients), study I likely suffered 
from overestimation of diagnostic performance from multiple testing. Therefore, study I had 
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the character of a pilot study indicating the likely maximum performance that could be 
expected at subsequent prospective evaluation. We chose to only focus on scar localization 
and not quantification in study I because a large portion of the same dataset had already been 
used to evaluate scar quantification.  
In our hunt for the best performing subset of the 2009 LBSS criteria, we employed a 
modified forward stepwise regression approach in which we determined the highest possible 
sensitivity for a given level of specificity and subsequently sought to choose the highest 
combination of both as the best strategy. The performance of each constructed subset of the 
2009 LBSS criteria is shown in figure 19. 
Figure 19. Diagnostic performance of identified subsets of 2009 LBSS criteria shown in 
a receiver operating characteristic curve 
 
 
 
 
 
 
Figure 19. The subsets of the 2009 LBSS criteria with optimal sensitivity for several 
predetermined levels of specificity to detect scar in given myocardial wall regions. The subset 
of criteria that was closest to the upper left corner was considered to have the optimal 
diagnostic performance for each respective myocardial wall region. The best subset of 2009 
LBSS criteria for detection of non-septal scar achieved a specificity of 95% and sensitivity of 
75 %. Figure adapted from Study I, with permission. 
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In summary, the results of study I provided two insights: 
1) The 2009 LBSS had limited performance in localizing myocardial scar into individual 
myocardial wall segments.  
2) A set of criteria was found to detect presence of myocardial scar located anywhere but 
the septum in LV with reasonable performance, perhaps enough to be of clinical 
utility.  
Although the non-septal set of criteria would have to be tested in an independent 
population and did not solely detect lateral scar, other studies had revealed that the CRT 
LV lead tips are implanted in all regions of the LV but the septum112. Furthermore, 
identified non-septal set of criteria was later found by an independent research group to 
be predictive of CRT response by echocardiography60. 
4.2 PERFORMANCE OF THE SELVESTER QRS SCORE IN A BROAD 
POPULATION IN SEVERAL CONDUCTION ABNORMALITIES: STUDY II 
 
At the time of commencement of study II, the performance of the 2009 Selvester QRS score 
conduction abnormality adaptations had only been preliminarily evaluated against CMR-LGE 
in small and carefully selected datasets99, 113, 114. We therefore sought to evaluate the 
performance in detecting, quantifying and localizing myocardial scar in a wider population in 
four of the conduction types added in 2009: LBBB, RBBB, LAFB and the combination of 
RBBB+LAFB. At Duke, there was a high volume of patients undergoing CMR. Although 
patients with conduction abnormalities are likely overrepresented in clinical CMR databases 
in general, they constitute only a minority of patients. Between August 2011 and January 
2013 there were 3962 patients who underwent both a CMR scan and an ECG at Duke 
University Medical Center. Out of these patients, there were 193 who had one of the included 
conduction abnormalities, a good quality ECG recording and a good quality CMR-LGE scan. 
They were distributed between conduction types according to table 2. 
 50 
In summary, we found that the Selvester QRS score tended to both overestimate scar extent 
and presence. Diagnostic performance in terms of scar detection was modest with AUC 
ranging from 0.62-0.65 across the four conduction types. The correlation between the ECG 
and CMR estimated scar size was weak, with low ICC in all conduction types (table 3). The 
results inspired the hypothesis that some criteria were particularly non-specific. Also, an 
attempt at adjusting the Selvester QRS scores for the LAFB and RBBB+LAFB conduction 
types by discounting certain criteria thought to be non-specific yielded only slight 
improvement. 
Table 3. Performance of the 2009 Selvester QRS score per conduction type (Study II) 
 
Abbreviations: AUC – Area under the curve. ICC – intraclass correlation coefficient. LAFB – 
Left anterior fascicular block. LBBB – left bundle branch block. RBBB – Right bundle branch 
block. Table reproduced from Study II, with permission. 
4.3 SPECIFICITIES OF THE 46 INDIVIDUAL CRITERIA COMPRISING THE 2009 
LBSS: STUDY III 
 
As a first step toward improving the ECG scar detection and quantification performance, we 
sought to investigate the specificities of individual criteria of the 2009 LBSS in order to 
determine if there were indeed highly non-specific criteria bogging down the performance of 
2009 LBSS as a whole. Out of the several available conduction types, we chose to focus on 
LBBB for two main reasons. Firstly, LBBB was the clinically most important conduction 
abnormality because of the association with mechanical LV dyssynchrony. Secondly, the 
theoretically simple sequential activation pattern of the LV from right to left (shown in figure 
7, panel A) was hypothesized to allow reasonably consistent ECG patterns and their readily 
detectable disrupting due to myocardial scar. We had also noted in previous studies that some 
criteria in the 2009 LBSS, such as location of the S’ notch or slur84 in the criteria for lateral 
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scar (listed in figure 15), were difficult to apply consistently. Therefore, we also measured 
interobserver variability on a per-criterion basis, rather than for the system as a whole, which 
had been previously reported to be excellent115.  
We did indeed find a great heterogeneity in specificity in the study population of 99 CMR-
determined scar free patients, which ranged between 41-100 percent across the 46 criteria. 
We found somewhat lower interobserver agreement compared to a previous study by Strauss 
et al (full agreement in 39% and 60% of ECGs, respectively)99, possibly because we only 
studied LBBB patients who may be more difficult to score than other conduction types. 
Moreover, we found varying interobserver agreement in the application of individual criteria, 
which ranged between 80-100 %. Specificity per criterion is shown in figure 20. 
Figure 20. Specificity of the 46 QRS morphology criteria in the 2009 LBSS (Study III) 
 
Figure 20. The specificity of each och the individual criterion in the left bundle branch block 
adaptation of the 2009 Selvester QRS score. Figure reproduced from study III, with 
permission. 
4.4 USING THE 2009 LBSS TO PREDICT RESPONSE TO CRT: STUDY IV  
 
Study IV commenced before the results of studies II and III were known. The Selvester QRS 
score in all conduction types had shown promising results in early validation versus CMR99. 
In study IV, paper ECG recordings from all 1820 patients in the MADIT-CRT database were 
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classified according to conduction type and then scored using previously published guide as a 
reference84. All ECG scoring was completed by Zak Loring and adjudication of difficult 
ECGs by David Strauss, both active at the US FDA at the time. A comprehensive analysis 
was performed in which the impact of Selvester QRS score on echocardiographic 
improvement and survival in both non-LBBB and LBBB subgroups was assessed. The ability 
of scar burden estimated by Selvester QRS scoring to predict heart failure event or death is 
summarized in figure 21.  
In summary, we found that patients with higher Selvester QRS scores had increased mortality 
in the LBBB subgroups of both study arms. However, higher Selvester QRS score could not 
predict who would benefit from CRT. Still, high QRS score was predictive of less 
improvement post-CRT, but not faster deterioration in the absence of CRT. In addition, the 
effect of QRS score on echocardiographic parameters was significant but of a small effect 
magnitude. Linear regression indicated that a high QRS score of 10, hypothetically 
corresponding to roughly 30% LV scar, translating into 2.7 percentage points of lesser LVEF 
improvement. In light of the results from studies II and III, the results may have reflected the 
weak but still significant correlation between Selvester QRS score and myocardial scar. The 
results still highlight the importance of separating post-CRT prognosis from CRT efficacy. 
Previous findings have indicated that high scar burden is associated with poorer outcome 
after CRT, but only a randomized study could determine whether high scar burden is a 
merely a general marker of poor prognosis regardless of CRT. In the setting of HF with 
LBBB and high scar burden with a prognosis equivalent to many malignant diseases, it may 
be unethical to withhold a beneficial treatment only because that treatment would work even 
better in other patients. Indeed, a study comparing the effect of HF etiology on CRT benefit 
found that patients with ischemic etiology, who generally have higher scar burden, still 
benefit from CRT despite comparatively poor response in the CRT arm of the study116.  
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Figure 21. Predictive power of Selvester QRS scoring in LBBB and non-LBBB 
subgroups of both study arms in study IV 
 
Figure 21. Forest plots showing the effect of scar burden estimated by Selvester QRS scoring 
on risk of heart failure event or death, with QRS score as a continuous variable (panel A) and 
as a dichotomized variable (panel B). Each QRS score is thought to represent scar burden 
equivalent to 3% of the left ventricular mass. Abbreviations: CRT-D – Cardiac 
resynchronization therapy with defibrillator. ICD – Implantable cardioverter defibrillator. 
HF – Heart failure. Figure reproduced from Study IV, with permission. 
4.5 IMPROVED ECG SCAR CHARACTERIZATION IN LBBB: STUDY V 
 
Study V was the largest and most complex study, in which we sought to assemble a large 
training set of patients with LBBB, known scar burden by CMR, and continuous ECG 
measurements to calibrate a new ECG scar screening tool using empirical data. The 
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theoretical groundwork had been laid down by the construction of the 2009 LBSS, shown in 
figure 15. Despite LBBB being relatively uncommon, clinical CMR databases had now 
grown so large since the general introduction of CMR-LGE imaging into clinical routine in 
the late 1990’s and early 2000’s that enough LBBB patients had undergone CMR. From the 
four participating centers, we were able to identify 325 patients with acceptable quality CMR 
and ECG measurements. We elected in study V to exclude patients who had more than 30 
days in between the ECG acquisition and the CMR scan, unless there was no scar and the 
ECG was recorded first. The 2009 LBSS can be broken down into 21 continuous and 4 
binary ECG variables. In addition to these, we elected to prospectively evaluate another 2 
continuous and 16 binary ECG variables, assigned to specific myocardial wall regions. These 
additional ECG parameters were prospectively defined by three investigators in conference 
based on previous findings regarding the LBBB conduction pattern summarized in figure 7. 
In order to measure some of these variables, especially those involving notches and slurs, we 
deemed it necessary to create dedicated ECG analysis software as summarized in figure 16. 
In analyzing the data, we first calculated the 2009 LBSS from the continuous ECG 
measurements for each patient and evaluated the performance. Results were largely 
consistent with those in study II, as both studies found an AUC to identify any scar of 0.62, 
with little improvement when various scar burden cutoffs were used so that only larger scars 
were counted as positive. Notably, there was no correlation between ECG and CMR scar in 
the 93 patients with ischemic scar. This absence of a correlation was surprising as dense focal 
ischemic scar would theoretically be easier to diagnose than more diffuse non-ischemic scar. 
We attempted to develop an improved ECG scar screening and quantifying tool using several 
parallel approaches, all of which resulted in alternate systems that in turn were then evaluated 
with regards to ability to detect and quantify scar. Firstly, we attempted two modifications of 
the 2009 LBSS with a maintained overall structure. One alternate system was created in 
which all criteria were eliminated that did not meet a 95% specificity threshold according to 
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the results in study III. The other was based on tuning all thresholds of the continuous 
variables in the 2009 LBSS to exactly 95% specificity and then removing all binary criteria 
not meeting the specificty threshold. Neither of these approaches resulted in meaningful 
improvement.  
Next, we used multivariate forward selection logistic regression to construct a model to detect 
presence of scar. This resulted in a significantly improved model compared to the 2009 LBSS 
(AUC 0.72 and 0.60, respectively, p<0.006). However, it should be acknowledged that the 
subgroup of patients with scar in the dataset was comprised of n=142 patients and there were 
44 original candidate variables in the model. Thus the ratio of predictor variables to the rarest 
outcome, traditionally known as events per variable (EPV) was 3.3. In order to create 
generalizable models, an EPV of 10 is traditionally recommended. We still judged the 
approach beneficial enough to yield valuable results, partly as study of an estimated 
maximum performance of the ECG for detecting scar, and partly as a method for yielding a 
simple hypothesis that could more easily be tested prospectively.  
Study V used multivariate forward selection linear regression to identify a model that could 
quantify myocardial scar burden. Unsurprisingly, an improvement was achieved in the 
training set compared to the 2009 LBSS although both methods had limited performance (r2= 
0.21 and 0.04, respectively, p<0.001). 
We further evaluated all a priori defined ECG variables with regards to identifying scar in 
their assigned myocardial wall region with performance expressed as AUC (table 4). Notably, 
for the individual ECG parameter that best detected myocardial scar, maximum 
positive/maximum negative amplitude ratio in lead I, we found an AUC comparable to the 
multivariate logistic model described above (AUC 0.71 versus 0.72, p=0.40). Although both 
results run the risk of having been inflated due to overfitting, the performance is comparable 
in terms of combined sensitivity and specificity to traditional infarction diagnosis by 
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pathological Q-waves in patients with no conduction abnormality83. Furthermore, even small 
scar, prevalent in LBBB patients, has been shown to be a prognostically important41, 45. Thus, 
the 12-lead ECG likely does not contain the information necessary to quantify scar, but may 
be able to determine scar presence also in LBBB. The results can be evaluated in an 
independent population to determine the generalizability of the findings, which would not 
require extensive and time consuming CMR measurements of scar quantity as in study V.  
Table 4. The ability of all evaluated ECG parameters to detect scar in their respective 
assigned myocardial wall regions (Study V) 
Abbreviations: Amp – Amplitude. AUC – Area Under the Curve. LBBB – Left Bundle Branch 
Block. InvMaxPos/MaxNeg amp – Inverted Maximum Positive Amplitude over Maximum 
Negative Amplitude Ratio. Table reproduced from study V manuscript. 
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5 CONCLUSIONS 
 
Studies I-V collectively show that the 2009 Selvester QRS score for scar detection, 
quantification and localization in presence of conduction abnormalities typically 
overestimates scar presence and extent. Furthermore, the standard 12-lead ECG likely does 
not contain information needed to accurately localize and quantify myocardial scar in 
presence of LBBB. However, there may be simple ECG signs that can diagnose presence of 
myocardial scar with potentially comparable accuracy to traditional Q-waves in patients with 
normal conduction. These ECG patterns will have to be evaluated in an independent 
population, the work of which is being planned within the research group. 
The specific conclusions for each paper were: 
I. The 2009 LBSS criteria likely can convey some information about myocardial 
scar localization, but not enough to effectively rule out myocardial scar in a 
particular region in a clinical setting.  
II. The conduction abnormality adaptations of the 2009 Selvester QRS score have 
limited agreement with CMR-LGE with regards to scar presence and extent, when 
evaluated in a broad population.  
III. Several individual criteria of the 2009 LBSS have prohibitively low specificity. 
IV. The 2009 Selvester QRS score is associated with increased risk of heart failure 
event or death regardless of CRT implantation. 
V. The 12-lead ECG is not a suitable modality to accurately quantify myocardial scar 
in presence of LBBB. However, there may be simple patterns in the 12-lead ECG 
that may be able to detect myocardial scar presence. 
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